卢帕他定联合转移因子口服液治疗慢性荨麻疹的临床观察  

Clinical Observation of Lupatadine Combined with Transfer Factor Oral Liquid in the Treatment of Chronic Urticaria

作　　者：郭亚茜 Guo Yaxi(Jinzhou Medical University,Jinzhou 121000 China)

机构地区：[1]锦州医科大学,辽宁锦州121000

出　　处：《锦州医科大学学报》2020年第6期55-58,共4页Journal of Jinzhou Medical University

基　　金：辽宁省教育厅资助项目,项目编号:JYTQN201729;辽宁省科技厅资助项目,项目编号:2020JH5/10100027。

摘　　要：目的探讨卢帕他定片联合口服因子治疗慢性荨麻疹(chronic spontaneous urticaria,CSU)的临床疗效、不良反应及安全性。方法收集本市2018年3月至2019年3月间皮肤科门诊就诊的70例慢性荨麻疹患者,按照随机数字表法分为两组,各35例,对照组接受常规剂量的卢帕他定片治疗,观察组接受卢帕他定片联合转移因子口服液治疗。两组患者均持续治疗6 w,采用ELISA检测方法检测两组患者血清中IL-33和IL-35的表达情况,通过瘙痒程度、风团数量、风团直径、瘙痒持续时间4项指标的评分总和对CSU疾病程度进行评价,根据症状积分下降指数(symptom score reduce index,SSRI)评价治愈例数。结果对照组和观察组患者血清的IL-33含量均有下降,差异显著(P<0.05),并且观察组与对照组相比,IL-33水平进一步下降,差异有统计学意义(P<0.05);两组患者血清中IL-35含量均较治疗前有所提高,差异有统计学意义(P<0.05),并且观察组与对照组相比,IL-35水平进一步提高,差异有统计学意义(P<0.05);对照组和观察组的症状积分均有所下降,差异有统计学意义(P<0.05),且观察组的症状积分较对照组进一步下降,差异统计学意义(P<0.05);对照组治疗后有效率74.29%,观察组治疗后有效率91.43%,两组有效率比较,差异有统计学意义(P<0.05);观察组和对照组发生不良反应的例数分别为3例和5例,不良反应的发生率分别为8.57%和14.29%,观察组和对照组患者的不良反应发生率差异无统计学意义(P>0.05)。结论卢帕他定联合转移因子能够有效改善IL-33、IL-35的表达水平,降低CSU患者的症状积分,提高治愈有效率,且不良反应少,具有较好的临床应用价值。Objective To investigate the clinical efficacy,adverse reactions and safety of rupatadine tablets combined with transfer factor oral liquid in the treatment of chronic urticaria(CSU).Methods 70 patients with chronic urticaria from March 2018 to March 2019 in our city were selected and divided into two groups according to the random number table method,with 35 cases in each group.Patients in the control group were treated with routine dose of rupatadine tablets,and those in the observation group were treated with rupatadine tablets combined with transfer factor oral liquid.The treatment of both groups continued for 6 weeks.The expression of IL-33 and IL-35 in serum of the two groups were detected by ELISA.The severity of CSU was evaluated by the scores of pruritus degree,number of wheals,diameter of wheals and duration of pruritus.The number of cured cases was evaluated according to symptom score reduce index(SSRI).Results Compared with the control group,the level of IL-33 in the observation group was further decreased(P<0.05);the level of IL-35 in the observation group was higher than that before treatment(P<0.05),and the level of IL-35 in the observation group was higher than that in the control group(P<0.05);the difference was statistically significant(P<0.05);the symptom scores of both the control group and the observation group decreased,and the difference was statistically significant(P<0.05);the symptom score of the observation group was further decreased than that of the control group,and the difference was statistically significant(P<0.05);the effective rate of the control group after treatment was 74.29%,the effective rate of the observation group(3 cases and 5 cases separately)was 91.43%,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group and the control group was 8.57%and 14.29%respectively.There was no significant difference(P>0.05).Conclusion Rupatadine combined with transfer factor can effectively improve the expression level of IL-33

关 键 词：卢帕他定 转移因子 荨麻疹 IL-33 IL-35 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]